Life Biosciences launches a Phase I trial for cellular reprogramming to treat age-related macular degeneration, challenging aging norms with FDA’s Plausible Mechanism Pathway, amid rising invest...
Exploring how mild mitochondrial stress through drugs like terbinafine and miglustat extends lifespan, with socioeconomic implications for longevity treatments. New research shows FDA-approved drugs c...
A new study on HMGB1’s Box A domain shows it can create DNA gaps, reversing age-related damage in non-human primates with up to 40% proteomic improvement, highlighting potential gene therapy for...
Recent studies show that FDA-approved antiretroviral FTC/TAF may slow aging by reducing retrotransposon activity, highlighting a promising gerotherapeutic approach with broad accessibility. Groundbrea...
Emerging studies show that aligning meals with circadian rhythms can reduce aging markers in organs like the heart and liver, offering practical strategies for longevity. Recent findings highlight how...
The FDA’s updated guidelines on cellular reprogramming, highlighted by Life Biosciences’ ER-100 trial for eye conditions, signal a pivotal shift that could accelerate anti-aging therapies,...
Analyzing recent rapamycin clinical trials for anti-aging, focusing on optimal dosing, safety, and the shift from off-label use to evidence-based protocols in longevity research. New human trials on r...
A landmark collaboration between Insilico Medicine and Eli Lilly leverages AI to accelerate drug discovery for aging-related diseases, with recent data showing reduced costs and faster development. Th...
Senolytic and senomorphic therapies, including Rubedo’s RLS-1496 in Phase 1 trials, target senescent cells to treat aging diseases, boosted by AI-driven discovery and rising investment. New seno...
Senolytic and senomorphic therapies are advancing with compounds like RLS-1496 and α-ESA-me targeting senescent cells. Experts highlight challenges in biomarkers and safety, pushing for personalized ...